GP, K., KM, R., SN, M., & LF, P. (2014). The absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles is not significantly impacted by the use of myeloid growth factors and predicts clinical outcomes in classical Hodgkin lymphoma regardless of their use. Dove Medical Press.
Chicago Style (17th ed.) CitationGP, Kaufman, Ristow KM, Markovic SN, and Porrata LF. The Absolute Lymphocyte/monocyte Ratio Recovery During ABVD Treatment Cycles Is Not Significantly Impacted by the Use of Myeloid Growth Factors and Predicts Clinical Outcomes in Classical Hodgkin Lymphoma Regardless of Their Use. Dove Medical Press, 2014.
MLA (8th ed.) CitationGP, Kaufman, et al. The Absolute Lymphocyte/monocyte Ratio Recovery During ABVD Treatment Cycles Is Not Significantly Impacted by the Use of Myeloid Growth Factors and Predicts Clinical Outcomes in Classical Hodgkin Lymphoma Regardless of Their Use. Dove Medical Press, 2014.